Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.93

-0.1%

2:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (51904)	1/12/2022 10:49:39 AM
From: Lance Bredvold	of 52153

Sorry to hear you were a victim Dew. You advised me a last June that PRTA (Prothena) had run up due to Aduhelm's approval at BIIB (Biogen) and I responded that it did not seem a reasonable reaction to me. I sold calls from $40 on up and eventually sold PRTA shares from $47 to $55 plus additional calls which expired worthless. Today restrictions on Aduhelm reimbursement by Medicare and other insurers has brought BIIB's stock down below where it was before the original approval. The shock to BIIB has resonated with LLY and even more with PRTA which is down 16% now. Again, I cannot see that the residual effect should be that significant. Consequently I have today purchased back nearly 1/4 of the shares I sold in December.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next